Journal Clinical Translational Hepatology 2021 vol 95 731737 DOI 1014218JCTH202000091 Review Article Druginduced Fatty Liver Disease Pathogenesis Treatment Tea Omanovic Kolaric12 Sonja Vukadin12 Vjera Nincevic12 Lucija Kuna12 Kristina Duspara1 Kristina Bojanic123 Nikola RaguzLucic12 George Y Wu4 Martina Smolic12 1University Osijek Faculty Medicine Osijek Croatia 2University Osijek Faculty Dental Medicine Health Osijek Croatia 3Health Center Osijek Osijek Croatia 4Department Medicine Division GastroenterologyHepatology University Connecticut Health Center Farmington CT USA Received 10 October 2020 Revised 8 February 2021 Accepted 1 July 2021 Published 14 September 2021 Abstract Metabolic dysfunctionassociated fatty liver disease com monly known MAFLD impacts global health epidemic proportions resulting morbidity mortality eco nomic burden enormous While attention given metabolic syndrome obesity offending fac tors growing incidence polypharmacy especially elderly greatly increased risk druginduced liver injury DILI general druginduced fatty liver dis ease DIFLD particular This review focuses tribution DIFLD DILI terms epidemiology patho physiology common drugs associated DIFLD treatment strategies Citation article Kolaric TO Nincevic V Kuna L Dus para K Bojanic K Vukadin S et al Druginduced fatty liver disease Pathogenesis treatment J Clin Transl Hepatol 202195731737 doi 1014218JCTH202000091 Introduction Druginduced liver injury DILI represents significant health problem USA European countries1 In prospective retrospective DILI studies2 annual incidence reported 27 100000 people Furthermore countries DILI associat ed acute liver failure The risk factors DILI include numerous interrelated factors advanced age sex drug dose genetic factors concomitant drugs excessive alcohol consumption nutrition preexisting liver disease Keywords Metabolic dysfunctionassociated fatty liver disease Druginduced liver injury Reactive oxygen species Free fatty acids Pharmacogenetics Abbreviations DIFLD druginduced fatty liver disease DILI druginduced liver injury DILIN DrugInduced Liver Injury Network DIS druginduced steatosis DISH druginduced steatohepatitis MAFLD metabolic dysfunction associated fatty liver disease MASH metabolic dysfunctionassociated stea tohepatitis MRC mitochondrial respiratory chain mtFAO mitochondrial fatty acid oxidation PNPLA3 patatinlike phospholipase 3 gene ROS reactive oxy gen species UDCA ursodeoxycholic acid ULN upper limit normal VLDL verylow density lipoprotein These authors contributed equally work Correspondence Martina Smolic University Osijek Faculty Medicine Department Pharmacology Faculty Dental Medicine Health Depart ment Pharmacology Biochemistry J Huttlera 4 Osijek 31000 Croatia ORCID httpsorcidorg000000026867826X Tel 38531512800 Fax 38531512833 Email martinasmolicmefoshr diabetes mellitus human immunodeficiency virus infection kidney failure3 Historically DILI divided types Type 1 dosedependent predictable type 2 results idiosyncratic reaction Type 2 doseindependent allergic immune mediated nonallergic nonimmunemediated4 The di agnosis DILI determined temporal relationship drug administration increased levels liver enzymes andor alkaline phosphatase56 exclusion causes liver damage rarely repeated drug challenge There standardized clinical test condition57 Druginduced cholestasis induced drugs disrupt bile acid transport inhibiting liver transporters involved bile flow6 Cholestasis severe metabolic dysfunctionassociated fatty liver disease MAFLD stages alcoholic hepatitis alcoholic cirrhosis8 Druginduced cirrhosis associated drugs cause fibrogenesis production extracellular matrix molecules9 MAFLD new concept proposed 2020 suggested replace term nonalcoholic fatty liver dis ease require exclusion alcoholic liver disease viral hepatitis1011 It accurate term people fatty liver dysmetab olism12 MAFLD known highly prevalent dis ease affecting quarter worlds adult population main cause chronic liver disease Europe USA1112 Besides high prevalence MAFLD alcohol abuse worldwide relationship present study population realworld populations concern10 The novel MAFLD criteria concentrate role dysmetabolism fat accumulation liver frequent driver fatty liver injury progression1314 When fatty liver injury progresses preexisting MAFLD combination drug administration defined dualetiology fatty liver disease10 Recently studies recommended MAFLD criteria ef ficient better perceiving patients higher risk fibrosis contrast nonalcoholic fatty liver disease criteria1115 MAFLD diagnosed patients hepatic manifestation metabolic syndrome diagnosed following conditions high glucose hypertension obesity high triglyc eride low highdensity lipoproteincholesterol16 There growing number clinical reports proposing cer tain drugs hepatotoxic overweight patients MAFLD contrast lean patients17 DILI MAFLD appears particular clinical situa tions1718 First antibiotics piperacillintazobactam telithromycin analgesics antipyretics like Copyright 2021 The Authors This article published terms Creative Commons AttributionNoncommercial 40 International License CC BYNC 40 permits noncommercial unrestricted use distribution reproduction medium provided following statement provided This article published Journal Clinical Translational Hepatology httpsdoiorg1014218JCTH202000091 viewed Journals website httpwwwjcthnetcom acetaminophen induce common acute liver injury It appears drugs like amiodar statins induce hepatotoxicity MAFLD patients17 Other drugs like antiretroviral agents corticosteroids methotrexate appear cause al teration simple fatty liver nonalcoholic steatohepatitis exacerbate necroinflammation preexisting steatosis fibrosis1920 Some drugs cause acute liver injury MAFLD illness connected modified activities metabolizing enzymes cytochromes P450 Regarding abovementioned information MAFLD frequently connected increased CYP2E1 activity decreased CYP3A4 activity higher glucuronide formation These enzymes sponsible metabolism lorazepam acetami nophen More vitro vivo research required cause mechanisms wherewith drugs xenobiotics hepatotoxic MAFLD known studies necessary ensuring success dealing issue especially considering worldwide epidemic obesity2122 Drugs represent alternative cause fatty liver dis ease term corresponds injury drug induced fatty liver disease DIFLD It specific form DILI characterized intracellular lipid accumulation hepatocytes steatotic changes predominant histopathological pattern2324 Although histopathologi cal finding required diagnosis finding specific11 DIFLD accompanied inflammation oxidative stress leads development drug induced steatohepatitis DISH25 Chronic liver injury leads hepatocyte death followed activation stellate cells finally results liver tissue fibrosis In addi tion numerous drugs cause progres sion steatohepatitis26 In 2015 Satapathy et al27 shown tamoxifen antiestrogenic drug treatment prevention breast cancer frequently associated hepatic steatosis rarely cir rhosis steatohepatitis Moreover authors emphasized chronic exposure amiodarone 4 4diethylami noethoxyhexestrol perhexiline maleate rarely led cir rhosis2728 It known phospholipidosis develops prolonged treatment drugs dosedependent manner However lead steatohepatitis Fur ther investigations needed elucidate mechanisms druginduced steatosis leads steatohepatitis consequently fibrosis Buggey et al29 reported amiodaroneinduced acute chronic liver injury steatosis leads necrosis bridging fibrosis earlystage cirrhosis It known amiodaroneinduced hepatotoxicity characterized histologic steatosis phospholipidosis fibrosis However case report histopathology showed absence steatosis phospholipidosis spite years amiodarone ingestion This suggests lack accepted histopathologic findings steatosis phospholipidosis exclude di agnosis This conclusion requires study confirmation Various studies confirmed role amiodarone induction liver cirrhosis possible fatal outcomes3032 Nevertheless adverse effects rare incidence 13 A longterm surveillance liver toxicity highrisk pa tients amiodarone suggested numerous researchers303133 Most drugs capable causing steatosis steatohep atitis known cationic amphiphilic structure34 These drugs divided groups including drugs cause steatosis steatohepatitis independently amiodarone perhexiline drugs accel erate latent metabolic dysfunctionassociated steatohepati Kolaric TO et al Druginduced fatty liver disease tis MASH tamoxifen drugs cause sporadic events steatosissteatohepatitis car bamazepine23 More details effects drugs liver tissue discussed sections Epidemiology DIFLD Recently reported annual incidences DILI varied widely populationbased studies 27 191 cases 10000035 Accordingly true incidence DIFLD general population remains unknown35 However drug induced steatosis DIS druginduced steatohepatitis DISH generally rare welldocumented forms DILI According DrugInduced Liver Injury Network DILIN approximately 27 DILI cases form steatosis histological injury36 In study Kleiner et al36 case diagnosed predomi nant pattern microvesicular steatosis remain ing cases showed combination macrovesicular steato sis inflammation Previously published descriptions pathologic changes DILI basis diagnostic classification DILIN prospective study Kleiner et al3637 To define patterns injury standard hepatopathological diagnostic criteria used38 Although included large proportion DIFLD DILI cases DILIN prevalence biased preexisting pres ence fatty liver The true data DIFLD epidemiology clearer eliminating diagnostic difficul ties deficiencies systematic reporting Histology DIFLD DIFLD present pure macrovesicular microvesicular steatosis DISH Histologically macrovesicular stea tosis accumulation large lipid vesicles triglyc erides occurs hepatocyte nucleus consequently dislocated periphery cell3639 As causes steatohepatitis aminotransferases usually moderately increased40 The presence triglycer ides associated deterioration mitochondrial fatty acid oxidation mtFAO decreased verylow density lipopro tein VLDL secretion stimulation novo lipogenesis direct activation transcription factors SREBP1c PPARγ development insulin resistance17274143 In microvesicular steatosis cytoplasm hepatocytes filled numerous small lipid vesicles nucleus remains center cell44 The severe impairment mtFAO leads increased esterification triglycerides known histologically related microvesicu lar steatosis2745 Steatohepatitis characterized lobular inflammation balloon degeneration hyaline Mallory bod ies perisinusoidal fibrosis233946 Addition ally mitochondrial dysfunction plays key role DIFLD direct indirect action oxidative stress increased production reactive oxygen species ROS mainly occur modification mitochondrial res piratory chain MRC1747 Microvesicular steatosis drug induced frequently result druginduced damage mitochondria4849 This type steatosis start small droplets fat cytoplasm increase macrovesicular steatosis characterized large fat drop lets shifted nucleus periphery Frequently macrovesicular steatosis present mixed large small droplets5051 Depending particular pathogenic mechanism lipotoxic drug DISDISH present micro macrovesicular steatosissteatohepatitis cases start acutely microvesicular injury52 The latency DIFLD clinical manifestations vary24 732 Journal Clinical Translational Hepatology 2021 vol 9 731737 Kolaric TO et al Druginduced fatty liver disease For DISDISH diagnosis liver biopsy standard means confirmation hepatic cell injury liver inflamma tion52 Risk factors occurrence DIFLD Some drugs cause progression MAFLD MASH cir rhosis worsen prognosis patients fatty liver17 This conversion MASH appears involve ge netic environmental factors17 MAFLD obesity enhance risk hepatotoxicity drugs18 The possible mechanisms certain drugs able ac celerate progression MAFLD include induction oxidative stress diminished mtFAO increased novo lipogenesis damaged egress VLDL liver cells53 Most DIFLD product direct impact drugs liver associated extended intake medications For example longterm administration drugs amiodarone perhexiline diethylami noethoxyhexestrol lead DISH Furthermore patients additional risk factors like obesity cardiometabolic risks prone exacerbation steatosis stea tohepatitis irinotecan tamoxifen methotrexate added therapy Insulin resistance hyper triglyceridemia combination antiepileptic drugs steroids lead steatohepatitis MASH DIFLD27 Fatty liver injury progression related factors insulin resistance adipose tissue dysfunction lipid aggrega tion oxidative endoplasmic reticulum stress Also increased gut permeability increased plasma endotoxin levels associated fatty liver5456 Besides environmental risk factors genetics plays significant role progression simple steatosis57 Among patients similar risk factors large interindivid ual variability phenotypic penetrance exists57 Various ge netic epidemiological twin studies shown strong heritability predisposition MAFLD57 Apart drugs intrinsic sex age ethnicity liver renal condition extrinsic environmental chemicals alcohol diet drugdrug interactions risk factors considered clinical algorithm associated fatty liver58 There growing evidence genetic contribution devel opment MASH environmental risk factors play main role development simple steatosis In twin epidemiological familial studies large variability exists phenotypic penetrance people related risk factors powerful heritability sen sitivity MAFLD noticed57 Studies role genetics DIFLD early phases studies needed augment understanding genetic variants risk factors progression DIFLD MAFLD Influence pharmacogenetics risk devel oping DIFLD Alterations genes involved pharmacokinetics phar macodynamics partially responsible variations drug response58 Part individuals predisposition development effects high doses certain drugs like methotrexate tamoxifen explained patients genetic makeup pharmacogenetics As mentioned methotrexate tamoxifen drugs cause macrovesicular hepatic steato sis linked DIFLD In context highdose methotrex ate toxicity important emphasize unpredict able interindividual variability significant The results previous studies pharmacogenetics high doses methotrexate differ contradic tory This partly explained significant differences pharmacogenetics populations3959 Several genotypes associated higher risk meth otrexate toxicity MTHFR 677TT reduced activity methylenetetrahydrofolate reductase leads di minished elimination methotrexate RFC1 80G A duced folate carrier 1 responsible methotrexate entrance cells ABCB1 C3435TT ATP binding cassette subfamily B member 1 reduced action MDR1 slower elimination methotrexate60 The metabolisms 5fluorouracil depends enzymatic activity dihydropyrimidine dehydrogenase Indeed vari ants 2A 13 enzyme related reduced tabolism 5fluorouracil lead effects61 Genetic alterations patatinlike phospho lipase 3 gene PNPLA3 affect plasma levels hepatic enzymes risk MAFLD development6263 including predisposition fibrosis progression6465 The abovemen tioned polymorphism powerful predictor inflamma tion steatosis fibrosis66 role PNPLA3 DIFLD pathogenesis remains obscure27 Polymorphisms PNPLA3 strongly associated ethnic interindividual vari ations liver fat content57 Hispanics higher tendency develop liver steatosis unlike African Americans67 In addition twin studies suggest 60 alanine transaminase variability ascribed genetic factors68 Slow metabolizers perhexiline Caucasians greater danger neuropathy steatohepatitis Perhexiline catabolized cytochrome P450 isoform 2D6 long halflife slow liver clearance slow metabolizers69 In recent years genetic factors steatosis studied utilizing genomewide association techniques Fur ther research area pharmacogenomics needed better understand numerous possible gene polymorphisms responsible increasing risk DIFLD velopment Drugs cause DIFLD Drugs shown cause macrovesicular liver steatosis glu cocorticoids amiodarone methotrexate estrogens tamox ifen nonsteroidal antiinflammatory drugs paracetamol 5fluorouracil metoprolol397072 Drugs associated microvesicular steatosis valproic acid tetracycline pirin ibuprofen zidovudine glucocorticoids2444 Drugs associated DISH valproic acid tamoxifen perhex iline amiodarone propranolol4473 It important recognize particular drugs cause acute liver damage fatty liver background increase danger chronic liver disease The hepatic ac cumulation fat necessarily stable DISDISH reversible74 In cases difficult elucidate fatty liver disease direct result effect hepatic cells consequence weight gain caused drugs antidepressants antipsychotics Pharmaceuticals induce progression ex acerbate preexisting fatty liver MASH fibrosis shown Table 117 Mechanisms DIFLD development The main mechanisms development DIFLD thought include lipogenesis generation free radi cals leading oxidative stress induction hepatocytes4475 Kim et al76 showed amiodarone caused increase short medium longchain acylcarnitines livers Journal Clinical Translational Hepatology 2021 vol 9 731737 733 Kolaric TO et al Druginduced fatty liver disease Table 1 Drugs specifically hepatotoxic DIFLD MAFLD obesity Acute liver injury Drugs Amiodaron Aspirin Acetaminophen Ibuprofen Isoflurane Fosipronil Halothane Vitamin A Valproat Acid Tetracycline Telithromycin Piperacillintazobactam NRTIs Zalcitabin Losartan Omeprazole Sorafenib Ticlopidine Troglitazone Exacerbation preexist ing fatty liver MASH Androgenic steroids Benzbromarone Corticosteroids Irinotecan Methotrexate Tamoxifen NRTIs Pentoxifylline Phenobarbital Rosiglitazone Tetracycline Promoting transition preexisting fatty liver MASH fibrosis cirrhosis Androgenic steroids Benzbromarone Corticosteroids Irinotecan Methotrexate Tamoxifen NRTIs nucleoside reverse transcriptase inhibitors Data Allard J et al17 Druginduced liver injury obesity nonalcoholic fatty liver disease EASL Clinical Practice Guidelines Druginduced liver injury rats highest increases involving levels acetylcar nitine The probable cause disturbances liv er tissue effect amiodarone mtFAO blocking activity carnitine palmitoyltransferase1 enzyme directly inhibiting mitochondrial βoxidation acylCoA acetylCoA inhibiting complexes I II MRC1977 Another proven mechanism amiodar oneinduced DIFLD triggering novo lipogenesis augmenting expression genes sterol regulatory ele mentbinding protein 1 thyroid hormoneinducible hepatic protein ATPcitrate synthase fatty acid synthase acyl CoA desaturase involved process lipo genesis78 Additionally Anthérieu et al78 demonstrated vitro amiodarone administration led overexpression genes involved formation lipid droplets ilipin4 adipose differentiationrelated protein Tamox ifen like amiodarone cationic amphiphilic compound accumulates liver tissue causing liver injury34 Its toxic effect achieved impairing mtFAO duction novo lipogenesis79 A possible mechanism induction hepatic steatosis includes upregulation SREBP1c downstream lipogenesis target genes24 Accumulation triglycerides stimulates microsomal triglyc eride transfer protein expression associated VLDL sembly secretion80 Several vivo studies confirmed role oxidative stress tamoxifen hepatotoxicity Like amiodarone causes reduction liver glutathione lev els accumulation oxidized form glutathione lipid peroxidation7581 Methotrexate especially polyglutamated tabolite stored hepatocytes exert hepato toxic effects82 Several mechanisms proposed hepatotoxic effect methotrexate including hampering folate entry mitochondria leads mitochondrial dysfunction generation ROS finally induction caspasedependent apoptosis548384 Another possible mechanism hepatotoxicity disruption intesti nal epithelial barrier methotrexate leads leaky gut syndrome progression fatty liver jury3454 5Fluorouracil irinotecan lasparaginase exert hepatosteatotic effects impairing mtFAO enhancing ROS accumulation hepatocytes2085 Valproate branchedchain fatty acid disrupts mtFAO leading accumulation triglycerides steatosis44 Valproate free acid form serve substrate mtFAO path ways competing free fatty acids After entering hepatic mitochondria conjugates coenzyme A causes deficiency enzyme44 Chronic valproate administration increases progression preexisting fatty liver disease inducing systemic insulin resistance weight gain8687 Tetracycline known causing DIFLD Mechanisms toxic effect include inhibition mtFAO inhibition MTP enzyme results ac cumulation VLDL decrease expression genes involved mtFAO peroxisome proliferatoractivated receptor alpha carnitine palmitoyltransferase I fatty acidbinding protein 1 enhancement ROS genera tion activation transcription factor ATF4 upregulates CYP2E1 specifically doxycycline mi nocycline34418889 Nucleoside reverse transcriptase inhibi tors zidovudine didanosine stavudine tenofovir abacavir capable inhibiting human DNA polymer ase γ leading decrease mitochondrial DNA replica tion9091 Consequently oxidative stress accumulation fat occur9091 All abovementioned mechanisms volved DIFLD development summarized Table 2 Current future directions treatment DI FLD A fairly common recommendation management DILI potential manifestation DIFLD drawal potential offending agent Timely exclusion problematic drugs lead recovery 95 patients improvement velop chronic liver disease92 Criteria withdrawal drugs causing DILI published 2009 Food Drug Administration93 summarized following guidelines follows alanine aminotransferase aspartate aminotransferase 8 upper limit normal ULN 5 ULN period 2 weeks 3 ULN combined international normalized ratio 15 total bilirubin 2 ULN levels alanine aminotransferaseaspartate ami notransferase higher 3 followed nausea fe ver fatigue vomiting rash tenderness pain right upper abdominal quadrant potential eosinophilia92 If adequate replacement hepatotoxic drug dose adjusted order manage primary disease especially intrinsic DILI92 Glucocorticoids treat DILI DI FLD riskbenefit assessment They beneficial patients notable signs auto immunity hypersensitivity drug withdrawal92 Ursodeoxycholic acid UDCA hepatoprotective effect including cholangiocytes stimulatory effect hepa tobiliary secretion prevents cellular apoptosis scribed 15 DILI patients94 The effectiveness UDCA DILI cases lies improvement liver function abnormalities relieving symptoms fatigue pru ritus jaundice9597 significantly improving liver tests98 possibly delaying liver transplantation99100 Beneficial effects UDCA shown cohort studies case reports administration following drugs cause liver injury chlorpromazine cyclosporine amoxicillinclavulanate ticlopidine flucloxacillin paraquat methotrexate97101105 Rarely individual case reports supported therapeutic properties UDCA One pediatric report amoxicillinclavulanic acid toxicity 4 years liver transplantation Amelioration 734 Journal Clinical Translational Hepatology 2021 vol 9 731737 Kolaric TO et al Druginduced fatty liver disease Table 2 Drugs cause DIFLD proposed mechanisms responsible toxicity Drugs cause DIFLD Proposed mechanisms Amiodarone Tamoxifen Methotrexate 5Fluorouracil irinotecan lasparaginase Valproate Tetracycline NRTIs Blockage CPT1 enzyme activity blockage mtFAO increase acetylcarnitine levels inhibition MRC I II complexes Trigger novo lipogenesis augmenting SREBP1 THRSP ACLY FASN SCD1 PLIN4 ADFP genes expression Reduction GSH levels Impairment mtFAO induction novo lipogenesis upregulation SREBP1c downstream genes Stimulation MTP expression VLDL assembly secretion Reduction GSH levels Effect mitochondrial activity hampering folate entry mitochondria generation ROS disruption intestinal epithelial barrier Impairment mtFAO enhancement ROS accumulation hepatocytes Competition FFAs mtFAO decrease CoA levels Induction systemic insulin resistance weight gain Inhibition MTP enzyme decrease PAARα CPTI FABP1 genes expression involved mtFAO Enhancement ROS generation activation ATF4 Inhibition human DNA polymerase γ decrease mitochondrial DNA replication induction oxidative stress ACLY ATPcitrate synthase ADFP adipose differentiationrelated protein ATF4 transcription factor 4 CoA coenzyme A CPT1 carnitine palmitoyltransferase1 CPTI carnitine palmitoyltransferase I FABP1 fatty acidbinding protein 1 FASN fatty acid synthase FFA free fatty acid GSH glutathione MTP microsomal triglyceride transfer protein PLIN4 perilipin4 SCD1 stearoylCoA desaturase SREBP1 sterol regulatory elementbinding protein 1 THRSP thyroid hormoneinducible hepatic protein amiodaroneinduced hepatotoxic effect achieved antioxidants Nacetylcysteine vitamins C E75 Further clinical trials humans needed confirm observations Conclusions DIFLD remains great challenge researchers cli nicians lack adequate diagnostic tools numerous underlying pathophysiologic mechanisms involved Therefore cases DIFLD unrecogniz ed confirmation diagnosis occurs later irreversible stages liver disease Elucidation pathways specific drugs cause DIFLD represents step forward development appropriate therapy It important emphasize drug withdrawal dose adjustment far best therapeutic recommendation comes DILIDIFLD cases Nevertheless treatments UDCA cholestasis shown benefit early stages98 However field needs studies especially use pharmacogenetics predict avoid DILI identifying individuals benefit phar macological interventions Funding The study funded grant Croatian Ministry Science Education dedicated multiyear institu tional funding scientific activity JJ Strossmayer University Osijek Osijek Croatia grant number IP10MEFOS2019 MS Support Herman Lopata Chair Hepatitis Research gratefully acknowledged GYW Conflict The authors conflict interests related pub lication Author contributions Conceived designed article critically revised manuscript MS TOK VN obtained funding pro vided administrative technical material support MS performed literature searches wrote manuscript VN LK KD KB updated text manuscript TOK NRL SV GYW performed figure generation TOK performed critical revision manuscript important intellectual content MS GYW References 1 Ding WX Yang L Alcohol druginduced liver injury Metabolism mech anisms pathogenesis potential therapies Liver Res 2019334 129131 doi101016jlivres201911006 2 Björnsson ES Global Epidemiology druginduced liver injury DILI Curr Hepatology Rep 201918274279 doi101007s1190101900475z 3 Weiler S Merz M KullakUblick GA Druginduced liver injury dawn biomarkers F1000Prime Rep 2015734 doi1012703P734 4 Kuna L Bozic I Kizivat T Bojanic K Mrso M Kralj E et al Models drug induced liver injury DILI Current issues future perspectives Curr Drug Metab 20181910830838 doi10217413892002196661805230 95355 5 Sundaram V Björnsson ES Druginduced cholestasis Hepatol Commun 201718726735 doi101002hep41088 6 Kolarić TO Ninčević V Smolić R Smolić M Wu GY Mechanisms patic cholestatic drug injury J Clin Transl Hepatol 2019718692 doi1014218JCTH201800042 7 Ghabril M Chalasani N Björnsson E Druginduced liver injury clinical update Curr Opin Gastroenterol 2010263222226 doi101097MOG 0b013e3283383c7c 8 Yip WW Burt AD Alcoholic liver disease Semin Diagn Pathol 2006233 4149160 doi101053jsemdp200611002 9 Padda MS Sanchez M Akhtar AJ Boyer JL Druginduced cholestasis Hepatology 201153413771387 doi101002hep24229 10 Eslam M Newsome PN Sarin SK Anstee QM Targher G RomeroGomez M et al A new definition metabolic dysfunctionassociated fatty liver dis ease An international expert consensus statement J Hepatol 2020731 202209 doi101016jjhep202003039 11 Eslam M Sanyal AJ George J MAFLD A consensusdriven proposed menclature metabolic associated fatty liver disease Gastroenterology 2020158719992014e1 doi101053jgastro201911312 12 Younossi ZM Longterm outcomes nonalcoholic fatty liver disease From nonalcoholic steatohepatitis nonalcoholic steatofibrosis Clin Gastroen terol Hepatol 201715811441147 doi101016jcgh201705029 13 Dongiovanni P Stender S Pietrelli A Mancina RM Cespiati A Petta S et al Causal relationship hepatic fat liver damage insulin Journal Clinical Translational Hepatology 2021 vol 9 731737 735 sistance nonalcoholic fatty liver J Intern Med 20182834356370 doi101111joim12719 14 Nasr P Fredrikson M Ekstedt M Kechagias S The liver fat pre dicts mortality development type 2 diabetes nonalcoholic fatty liver disease Liver Int 202040510691078 doi101111liv14414 15 Lin S Huang J Wang M Kumar R Liu Y Liu S et al Comparison MAFLD NAFLD diagnostic criteria real world Liver Int 20204092082 2089 doi101111liv14548 16 Abou Assi R Abdulbaqi IM Siok Yee C The evaluation drug delivery nanocarrier development pharmacological briefing metabolicas sociated fatty liver disease MAFLD An update Pharmaceuticals Basel 2021143215 doi103390ph14030215 17 Allard J Le Guillou D Begriche K Fromenty B Druginduced liver injury obesity nonalcoholic fatty liver disease Adv Pharmacol 20198575 107 doi101016bsapha201901003 18 Massart J Begriche K Moreau C Fromenty B Role nonalcoholic fatty liver disease risk factor druginduced hepatotoxicity J Clin Transl Res 2017Suppl 1212232 doi1018053jctres032017S1006 19 Massart J Begriche K Buron N Porceddu M BorgneSanchez A Fromenty B Druginduced inhibition mitochondrial fatty acid oxidation steato sis Curr Pathobiol Rep 20131147157 doi101007s401390130022y 20 Meunier L Larrey D Chemotherapyassociated steatohepatitis Ann Hepa tol 2020196597601 doi101016jaohep201911012 21 Zheng KI Fan JG Shi JP Wong VW Eslam M George J et al From NAFLD MAFLD redefining moment fatty liver disease Chin Med J Engl 20201331922712273 doi101097CM90000000000000981 22 Ferron PJ Gicquel T Mégarbane B Clément B Fromenty B Treatments Covid19 patients preexisting metabolic dysfunctionassociated fatty liver disease A potential threat druginduced liver injury Biochimie 2020179266274 doi101016jbiochi202008018 23 Grieco A Forgione A Miele L Vero V Greco AV Gasbarrini A et al Fatty liver drugs Eur Rev Med Pharmacol Sci 200595261263 24 Rabinowich L Shibolet O Drug induced steatohepatitis An uncommon cul prit common disease Biomed Res Int 20152015168905 doi101155 2015168905 25 Farrell GC Drugs steatohepatitis Semin Liver Dis 2002222185 194 doi101055s200230106 26 Özkan A Stolley D Cressman ENK McMillin M DeMorrow S Yankeelov TE et al The influence chronic liver diseases hepatic vasculature A liver onachip review Micromachines Basel 2020115487 doi103390 mi11050487 27 Satapathy SK Kuwajima V Nadelson J Atiq O Sanyal AJ Druginduced fatty liver disease An overview pathogenesis management Ann Hepatol 2015146789806 doi105604166526811171749 28 Kotiloglu G Aki ZS Ozyilkan O Kutlay L Tamoxifeninduced cirrhotic process Breast J 200176442443 doi101046j152447412001 07613x 29 Buggey J Kappus M Lagoo AS Brady CW Amiodaroneinduced liver jury cirrhosis ACG Case Rep J 201522116118 doi1014309 crj201523 30 Tsuda T Tada H Tanaka Y Nishida N Yoshida T Sawada T et al Amiodar oneinduced reversible irreversible hepatotoxicity case reports J Med Case Rep 201812195 doi101186s1325601816298 31 Daneshvar F Amiodaroneinduced cirrhosis A known underrecog nized complication J Am Coll Cardiol 20207511_Supplement_12307 32 Lewis JH Ranard RC Caruso A Jackson LK Mullick F Ishak KG et al Amiodarone hepatotoxicity prevalence clinicopathologic correla tions 104 patients Hepatology 198995679685 doi101002 hep1840090504 33 Huang CH Lai YY Kuo YJ Yang SC Chang YJ Chang KK et al Amiodarone risk liver cirrhosis nationwide populationbased study Ther Clin Risk Manag 201915103112 doi102147TCRMS174868 34 Schumacher JD Guo GL Mechanistic review druginduced steatohepa titis Toxicol Appl Pharmacol 201528914047 doi101016jtaap 201508022 35 Björnsson ES Epidemiology predisposing factors outcomes drugin duced liver injury Clin Liver Dis 2020241110 doi101016jcld2019 08002 36 Kleiner DE Chalasani NP Lee WM Fontana RJ Bonkovsky HL Watkins PB et al Hepatic histological findings suspected druginduced liver injury sys tematic evaluation clinical associations Hepatology 2014592661 670 doi101002hep26709 37 Zimmerman HJ Hepatotoxicity The adverse effects drugs chemical liver 2nd ed Lippincot Williams Wilkins Philadelphia 1999 38 Macsween RMN Burt AD Portmann BC Ishak KG Scheurer PJ Anthony PP et al Pathology liver 4th edition Diagn Cytopathol 20032943 doi101002dc10338 39 Ramachandran R Kakar S Histological patterns druginduced liver dis ease J Clin Pathol 2009626481492 doi101136jcp2008058248 40 Chalasani N Bonkovsky HL Fontana R Lee W Stolz A Talwalkar J et al Features outcomes 899 patients druginduced liver injury The DILIN prospective study Gastroenterology 2015148713401352e7 doi101053jgastro201503006 41 Lettéron P Sutton A Mansouri A Fromenty B Pessayre D Inhibition microsomal triglyceride transfer protein mechanism drug induced steatosis mice Hepatology 2003381133140 doi101053 jhep200350309 42 Lauressergues E Staels B Valeille K Majd Z Hum DW Duriez P et al An tipsychotic drug action SREBPsrelated lipogenesis cholesterogen esis primary rat hepatocytes Naunyn Schmiedebergs Arch Pharmacol Kolaric TO et al Druginduced fatty liver disease 20103815427439 doi101007s0021001004994 43 Chaggar PS Shaw SM Williams SG Effect antipsychotic medica tions glucose lipid levels J Clin Pharmacol 2011515631638 doi1011770091270010368678 44 Miele L Liguori A Marrone G Biolato M Araneo C Vaccaro FG et al Fatty liver drugs sides coin Eur Rev Med Pharmacol Sci 2017211 Suppl8694 45 Fromenty B Pessayre D Inhibition mitochondrial betaoxidation mechanism hepatotoxicity Pharmacol Ther 1995671101154 doi1010160163725895000126 46 Dowman JK Tomlinson JW Newsome PN Pathogenesis nonalcoholic fatty liver disease QJM 201010327183 doi101093qjmedhcp158 47 Pessayre D Berson A Fromenty B Mansouri A Mitochondria steatohepa titis Semin Liver Dis 20012115769 doi101055s200112929 48 Begriche K Massart J Robin MA BorgneSanchez A Fromenty B Drug induced toxicity mitochondria lipid metabolism mechanistic diversity deleterious consequences liver J Hepatol 2011544773794 doi101016jjhep201011006 49 Suzuki A Brunt EM Kleiner DE Miquel R Smyrk TC Andrade RJ et al The use liver biopsy evaluation discrimination idiopathic autoimmune hepatitis versus druginduced liver injury Hepatology 2011543931939 doi101002hep24481 50 Crawford JM Histologic findings alcoholic liver disease Clin Liver Dis 2012164699716 doi101016jcld201208004 51 Fromenty B Berson A Pessayre D Microvesicular steatosis steatohep atitis role mitochondrial dysfunction lipid peroxidation J Hepatol 199726Suppl 11322 doi101016s0168827897823288 52 Pavlik L Regev A Ardayfio PA Chalasani NP Druginduced steatosis steatohepatitis The search novel serum biomarkers potential biomarkers nonalcoholic fatty liver disease nonalcoholic steatohep atitis Drug Saf 2019426701711 doi101007s40264018007902 53 Lee J Homma T Kurahashi T Kang ES Fujii J Oxidative stress triggers lipid droplet accumulation primary cultured hepatocytes activating fatty acid synthesis Biochem Biophys Res Commun 20154641229235 doi101016jbbrc201506121 54 Miele L Valenza V La Torre G Montalto M Cammarota G Ricci R et al Increased intestinal permeability tight junction alterations nonalco holic fatty liver disease Hepatology 200949618771887 doi101002 hep22848 55 Cani PD Amar J Iglesias MA Poggi M Knauf C Bastelica D et al Meta bolic endotoxemia initiates obesity insulin resistance Diabetes 2007 56717611772 doi102337db061491 56 Tilg H Moschen AR Evolution inflammation nonalcoholic fatty liver dis ease multiple parallel hits hypothesis Hepatology 20105251836 1846 doi101002hep24001 57 Dongiovanni P Valenti L Genetics nonalcoholic fatty liver disease Me tabolism 201665810261037 doi101016jmetabol201508018 58 Morse BL Kim RB Is personalized medicine dream reality Crit Rev Clin Lab Sci 2015521111 doi103109104083632014950407 59 Bozina N Farmakogenomika u personaliziranoj medicini priručnik posli jediplomski tečaj stalnog usavršavanja I kategorije Medicinska Naklada Zagreb 2019280str 60 Suthandiram S Gan GG Zain SM Bee PC Lian LH Chang KM et al Effect polymorphisms methotrexate pathway genes methotrexate toxic ity plasma levels adults hematological malignancies Pharmacog enomics 2014151114791494 doi102217pgs1497 61 Lunenburg CATC van der Wouden CH Nijenhuis M Crommentuijnvan Rhenen MH BoerVeger NJ Buunk AM et al Dutch Pharmacogenet ics Working Group DPWG guideline genedrug interaction DPYD fluoropyrimidines Eur J Hum Genet 2020284508517 doi101038 s4143101905400 62 Romeo S Kozlitina J Xing C Pertsemlidis A Cox D Pennacchio LA et al Genetic variation PNPLA3 confers susceptibility nonalcoholic fatty liver disease Nat Genet 2008401214611465 doi101038ng257 63 Yuan X Waterworth D Perry JR Lim N Song K Chambers JC et al Pop ulationbased genomewide association studies reveal loci influencing plasma levels liver enzymes Am J Hum Genet 2008834520528 doi101016jajhg200809012 64 Valenti L Pelusi S Redefining fatty liver disease classification 2020 Liver Int 202040510161017 doi101111liv14430 65 Romeo S Sentinelli F Cambuli VM Incani M Congiu T Matta V et al The 148M allele PNPLA3 gene associated indices liver damage ear ly life J Hepatol 2010532335338 doi101016jjhep201002034 66 Sookoian S Pirola CJ Metaanalysis influence I148M variant patatinlike phospholipase domain containing 3 gene PNPLA3 sus ceptibility histological severity nonalcoholic fatty liver disease Hepa tology 201153618831894 doi101002hep24283 67 Browning JD Szczepaniak LS Dobbins R Nuremberg P Horton JD Cohen JC et al Prevalence hepatic steatosis urban population United States impact ethnicity Hepatology 200440613871395 doi101002 hep20466 68 Makkonen J Pietiläinen KH Rissanen A Kaprio J YkiJärvinen H Genetic factors contribute variation serum alanine aminotransferase activity independent obesity alcohol study monozygotic dizygotic twins J Hepatol 200950510351042 doi101016jjhep200812025 69 Morgan MY Reshef R Shah RR Oates NS Smith RL Sherlock S Impaired oxidation debrisoquine patients perhexiline liver injury Gut 1984251010571064 doi101136gut25101057 70 Marino JS Stechschulte LA Stec DE NestorKalinoski A Coleman S Hinds TD Jr Glucocorticoid receptor β induces hepatic steatosis augmenting inflammation inhibition peroxisome proliferatoractivated recep 736 Journal Clinical Translational Hepatology 2021 vol 9 731737 Kolaric TO et al Druginduced fatty liver disease tor PPAR α J Biol Chem 2016291502577625788 doi101074jbc M116752311 71 Grieco A Vecchio FM Natale L Gasbarrini G Acute fatty liver malaria prophylaxis mefloquine Lancet 19993539149295296 doi10 1016S0140673605749321 72 Bruno S Maisonneuve P Castellana P Rotmensz N Rossi S Maggioni M et al Incidence risk factors nonalcoholic steatohepatitis prospective study 5408 women enrolled Italian tamoxifen chemoprevention trial BMJ 20053307497932 doi101136bmj38391663287E0 73 Ninčević V Omanović Kolarić T Roguljić H Kizivat T Smolić M Bilić Ćurčić I Renal benefits SGLT 2 inhibitors GLP1 receptor agonists Evidence supporting paradigm shift medical management type 2 diabetes Int J Mol Sci 201920235831 doi103390ijms20235831 74 Amacher DE Chalasani N Druginduced hepatic steatosis Semin Liver Dis 2014342205214 doi101055s00341375960 75 Akbay E Erdem B Ünlü A Durukan AB Onur MA Effects Nacetyl cysteine vitamin E vitamin C liver glutathione levels following ami odarone treatment rats Kardiochir Torakochirurgia Pol 201916288 92 doi105114kitp201986361 76 Kim G Choi HK Lee H Moon KS Oh JH Lee J et al Increased hepatic acylcarnitines oral administration amiodarone rats J Appl Toxicol 202040710041013 doi101002jat3960 77 Fromenty B Fisch C Labbe G Degott C Deschamps D Berson A et al Amiodarone inhibits mitochondrial betaoxidation fatty acids pro duces microvesicular steatosis liver mice J Pharmacol Exp Ther 1990255313711376 78 Anthérieu S Rogue A Fromenty B Guillouzo A Robin MA Induction ve sicular steatosis amiodarone tetracycline associated upreg ulation lipogenic genes HepaRG cells Hepatology 20115361895 1905 doi101002hep24290 79 Cole LK Jacobs RL Vance DE Tamoxifen induces triacylglycerol accumula tion mouse liver activation fatty acid synthesis Hepatology 201052412581265 doi101002hep23813 80 Zhao F Xie P Jiang J Zhang L An W Zhan Y The effect mecha nism tamoxifeninduced hepatocyte steatosis vitro Int J Mol Sci 201415340194030 doi103390ijms15034019 81 Suddek GM Protective role thymoquinone liver damage induced tamoxifen female rats Can J Physiol Pharmacol 2014928640644 doi101139cjpp20140148 82 Kremer JM Galivan J Streckfuss A Kamen B Methotrexate metabolism analysis blood liver rheumatoid arthritis patients Association hepatic folate deficiency formation polyglutamates Arthritis Rheum 1986297832835 doi101002art1780290703 83 Tabassum H Parvez S Pasha ST Banerjee BD Raisuddin S Protective ef fect lipoic acid methotrexateinduced oxidative stress liver mi tochondria Food Chem Toxicol 201048719731979 doi101016jfct 201004047 84 Bath RK Brar NK Forouhar FA Wu GY A review methotrexateasso ciated hepatotoxicity J Dig Dis 20141510517524 doi1011111751 298012184 85 Labbe G Pessayre D Fromenty B Druginduced liver injury mito chondrial dysfunction mechanisms detection preclinical safety studies Fundam Clin Pharmacol 2008224335353 doi101111j1472 8206200800608x 86 Patel V Sanyal AJ Druginduced steatohepatitis Clin Liver Dis 2013 174533546 doi101016jcld201307012 87 Luef G Rauchenzauner M Waldmann M Sturm W Sandhofer A Seppi K et al Nonalcoholic fatty liver disease NAFLD insulin resistance li pid profile antiepileptic drug treatment Epilepsy Res 20098614247 doi101016jeplepsyres200904004 88 Szalowska E van der Burg B Man HY Hendriksen PJ Peijnenburg AA Model steatogenic compounds amiodarone valproic acid tetracycline alter lipid metabolism different mechanisms mouse liver slices PLoS One 201491e86795 doi101371journalpone0086795 89 Brüning A Brem GJ Vogel M Mylonas I Tetracyclines cause cell stressdependent ATF4 activation mTOR inhibition Exp Cell Res 20143202281289 doi101016jyexcr201311012 90 Banerjee A Abdelmegeed MA Jang S Song BJ Zidovudine AZT hepatic lipid accumulation implication inflammation oxidative endoplasmic reticulum stress mediators PLoS One 2013810e76850 doi101371 journalpone0076850 91 Gardner K Hall PA Chinnery PF Payne BA HIV treatment associated mi tochondrial pathology review 25 years vitro animal human stud ies Toxicol Pathol 2014425811822 doi1011770192623313503519 92 Yu YC Mao YM Chen CW Chen JJ Chen J Cong WM et al CSH guidelines diagnosis treatment druginduced liver injury Hepatol Int 2017113221241 doi101007s1207201797932 93 Ford R Schwartz L Dancey J Dodd LE Eisenhauer EA Gwyther S et al Lessons learned independent central review Eur J Cancer 2009452268274 doi101016jejca200810031 94 Wree A Dechêne A Herzer K Hilgard P Syn WK Gerken G et al Steroid ursodesoxycholic Acid combination therapy severe druginduced liver injury Digestion 20118415459 doi101159000322298 95 Cicognani C Malavolti M MorselliLabate AM Sama C Barbara L Flutamide induced toxic hepatitis Potential utility ursodeoxycholic acid administra tion toxic hepatitis Dig Dis Sci 1996411122192221 doi101007 BF02071403 96 Piotrowicz A Polkey M Wilkinson M Ursodeoxycholic acid treatment flucloxacillinassociated cholestasis J Hepatol 1995221119120 doi101016016882789580272x 97 Kallinowski B Theilmann L Zimmermann R Gams E Kommerell B Stiehl A Effective treatment cyclosporineinduced cholestasis hearttrans planted patients treated ursodeoxycholic acid Transplantation 1991 51511281129 doi1010970000789019910500000041 98 Velayudham LS Farrell GC Druginduced cholestasis Expert Opin Drug Saf 200323287304 doi1015171474033823287 99 Poupon RE Poupon R Balkau B Ursodiol longterm treatment primary biliary cirrhosis The UDCAPBC Study Group N Engl J Med 19943301913421347 doi101056NEJM199405123301903 100 Poupon RE Lindor KD CauchDudek K Dickson ER Poupon R Heathcote EJ Combined analysis randomized controlled trials ursodeoxycholic acid primary biliary cirrhosis Gastroenterology 19971133884890 doi101016s0016508597701835 101 Bataller R Bragulat E Nogué S Görbig MN Bruguera M Rodés J Pro longed cholestasis acute paraquat poisoning skin absorp tion Am J Gastroenterol 200095513401343 doi101111j1572 0241200002021x 102 Katsinelos P Vasiliadis T Xiarchos P Patakiouta F Christodoulou K Pilpi lidis I et al Ursodeoxycholic acid UDCA treatment amoxycil linclavulanate potassium Augmentininduced intrahepatic cholestasis report cases Eur J Gastroenterol Hepatol 2000123365368 doi1010970004273720001203000017 103 Wengrower D Possible ticlopidineinduced cholestatic jaundice Am Fam Physician 200062612581264 104 Hunt CM Washington K Tetracyclineinduced bile duct paucity 1994107618441847 cholestasis Gastroenterology prolonged doi1010160016508594908303 105 Uraz S Tahan V Aygun C Eren F Unluguzel G Yuksel M et al Role ursodeoxycholic acid prevention methotrexateinduced liver toxicity Dig Dis Sci 200853410711077 doi101007s1062000799493 Journal Clinical Translational Hepatology 2021 vol 9 731737 737